Member Info for chrishutch

I might have to buy some just to prove the MMS are awake! Same on few shares this morning.

Good to see I think we will be in the 5s today

Paris and Barcelona this week and next week in Geneva and Lausanne

Hi, James, I get that, you are not the only one to mention it and I see your point, glad to hear you still have your shares!

Yes, hopefully it will be the start of a better PR and decent newsflow. Also great that his interests are aligned with our own and RNS states an update on the project and other initiatives

:-)

James lots of news flow of things that other companies only dream of. Share price closed up yet again and the team are not resting. You can expect things to keep getting better and better.

Maybe watch again

https://www.proactiveinvestors.co.uk/companies/news/904258/-watershed-moment--for-integumen-with-multi-year-deals-and-new-psoriasis-skin-model-904258.html

Thanks Retireby40

There is the Sharesmag event on Thursday which if my understanding is correct is a video presentation so that should spark a bit of interest and hopefully get the price moving up to where should be.

Hopefully, this will look like a genius move soon.

Does anyone here know what the l'oreal meeting today was about. Or where in the world the photo was taken? Is it barcalona could it be Luxemburg? France perhaps?

They are in Barca this week at the Cosmetics Business Summit 2019

I know right - nearly 2 million in one trade (popped up late)

Thanks, Brad for the kind words but no need to feel responsible. I understood that the low number of shares here meant the price would move around a bit. I have actually been adding into the weakness as it can turn around and move up as quickly as it dropped and you know how these things work - one minute you are thinking should I add and the next the share price has moved up and the opportunity is gone.

Not as high a share price as I think we deserved or would have liked but it is only the beginning of an upward journey.

I challenge anyone to find another company with this much excitement, potential or world-changing products?

Integumen has signed multi-year agreements with two major international
cosmetics companies for recurring LabskinAI services. These framework
agreements are already being rolled out in the US, Asia and the EU markets and
low six-figure aggregate payments have been received by the company. With
Integumen also anticipating contract extensions with existing clients in the nearterm, the management is confident that group revenue will exceed £1.0m in the
current financial year.

Under the initial agreements with the two global cosmetics companies, R&D teams in
the US, Asia and the EU will connect and collaborate with Integumen’s LabskinAI
virtual lab in regard to testing existing products and developing new products.
Integumen’s new clients will be able to make full use of the company’s healthy and
diseased living skin models and benefit from the analysis generated by the LabskinAI
platform.

Both of these benchmark agreements are data driven and recognise that non-animal
testing on Labskin human skin equivalents, in combination with AI analysis, represents
a paradigm shift for the skincare industry. Integumen notes that clients are able to
assess how topical skincare formulations react both on top of and deeper inside the
skin microbiome in order to create safer and more cost-effective products that also
meet exacting international compliance standards.

In separate news, the Labskin AI combined teams of microbiology and computer
science recently disclosed the completion of an artificially intelligent, virtual psoriasis
skin model at the AI Awards 2019 in Dublin.

The company used 671 anonymous patient samples taken from psoriasis lesions on the
patients’ skin with the goal of generating a generalised solution for diseased skin.
Following genomic sequencing of the samples, the datasets generated identified 216
species of microbiota (bacteria, virus and fungi) which were all confirmed using
several different AI algorithms.

Following testing of the various types and a cross-validation process, the company
identified a reliable psoriasis model. Within this, 33 species were identified that are
critical to the success of the LabskinAI diseased skin model for analysing psoriasis.
Addition of further data is expected to increase the accuracy of the model and the AI
dataset can be used as the framework to develop other diseased skin models including
rosacea and acne.

Psoriasis is believed to afflict some 4.8% of the global population and burden on
health service providers is significant. In the US alone, the annual cost of psoriasis was
estimated to be $11.25bn in 2008 representing only one of many large potential
markets for advances in the treatment of this disease.

Integumen is making progress on a broad front as the commercial potential of
LabskinAI is delivering both sales....

To see more..
https://twitter.com/gjbrandon/status/1181208193051058177?s=20

exactly. I think whatever direction the company takes over the next 3-5 years it will do us early shareholders very well.

Also notice there is a broker note out

Also noticed the volume jump - 16.8 million shares traded so I would guess given the small rise that we have cleared quite a few short term traders and are primed for a move higher with the new investors and those that managed to squeeze a top in.

Anyone else listen to the interview more than once?

47 posts that has to be a record. Skin is getting noticed by a much wider crowd!

never resting are they?! :-)

The Cosmetics Business Regulatory Summit will be held 8-9 October in Barcelona.